Outcomes of Drug-Eluting Stents in comparison to Bare Metal Stents in Cancer Patients with Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis

Table 1

Characteristics of included studies.

Study	Design	Population	Experimental arm	Control arm	Endpoints	Follow-up duration
Ahmed et al. [24]	Single-center retrospective cohort study	Cancer patients who underwent PCI using BMS or DES	PCI using BMS	PCI using DES	Stent thrombosis	2 years 10 months
Munawar et al. [23]	Retrospective cohort study	Patients with concomitant diagnosis of cancer undergoing PCI between January 2004 and December 2014 were identified in the National Inpatient Sample	PCI using BMS	PCI using DES	In-hospital mortality and stent thrombosis	10 years
Guo et al. [7]	Retrospective cohort study	Cancer patients undergoing PCI at Mayo Clinic Rochester from January 1, 2003, to December 31, 2013	PCI using BMS	PCI using DES	All-cause mortality, MI, and revascularization rate	10 years
Potts et al. [25]	Retrospective cohort study	Patients undergoing PCI between January 2004 and December 2014 were identified in the National Inpatient Sample	Patients with current/previous cancer undergoing PCI	Patients without current/previous cancer undergoing PCI	In-hospital mortality, bleeding, and stroke	10 years

BMS, bare metal stent; DES, drug-eluting stent.